All these results indicate that AMPK, by downregulating PGC‐1α and PPARγ and by upregulating HIF‐1α, could induce HCC stem cell reprogramming and restore sorafenib sensitivity. The gene discussed is PPARGC1A; the disease is hepatocellular carcinoma.